 Biofrontera AG NASDAQ ticker symbol: BFRA, ISIN: DE0006046113, an international biopharmaceutical company, announces that it has entered into a Binding Term Sheet with Maruho Co, Ltd, Osaka, Japan Maruho, which sets out the main terms of a future license agreement. The agreement covers the commercialization of Ameluz by Maruho in East Asia and Oceania. Biofrontera AG grants Maruho an exclusive license to develop and market Ameluz for all indications in East Asia and Oceania. 